Botanical Therapeutics

Many prescription drugs currently on the market were originally isolated from plants and/or are semi-synthetic analogues of phytochemicals.

It has been estimated that around 25 % of all prescription drugs currently in use are of plant origin.

Traditionally, plant-based medicines were used in the form of infusions, tinctures and extracts, essential oils, powders, poultices and other herbal preparations.

The current trend is to isolate and characterise the individual phytochemical components with the aim of producing an analogue of increased bioactivity and bioavailability.

Such studies have given rise to many useful drugs such as quinine (from the bark of  cinchona) and digoxin (from fox glove, Digitalis lanta).

It has, however, been observed that the bioactivities of essential oils and other “crude” botanical extracts are often considerably enhanced, and sometimes totally different to those seen for the individual components.

Several studies indicate that the blending of essential oils can give rise to synergistic antimicrobial effects.

Manuka Bioscience’s “Botanical Therapeutics” strategy is to trial various combinations of combining its “hero” ingredient mānuka oil β-triketones with secondary bioactives in the form of potent, well characterised, low allergenic, commercially available essential oils  (or key EO constituents).

This demonstrated the significant global opportunity to develop a range of high efficacy, broad spectrum cosmeceuticals and pharmaceuticals and new intellectual property which comprised the preclinical pre-clinical project which we called “Botanical Therapeutics”.